TOVX
Theriva Biologics Inc (TOVX)
Healthcare • NYSE MKT • $0.35-1.67%
- Symbol
- TOVX
- Exchange
- NYSE MKT
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.35
- Daily Change
- -1.67%
- Market Cap
- $16.25M
- Trailing P/E
- N/A
- Forward P/E
- -1.77
- 52W High
- $0.86
- 52W Low
- $0.16
- Analyst Target
- $2.50
- Dividend Yield
- N/A
- Beta
- N/A
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal a…
Company websiteResearch TOVX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.